Orchidia Pharmaceutical

What Orchidia Pharmaceutical does

Orchidia Pharmaceutical Industries is an Egyptian pharmaceutical manufacturer founded in 1993 (originally as Orchidia Promotions, rebranded to Orchidia Pharma in 2003) and headquartered in Cairo with manufacturing operations in Al-Obour City. The company specializes in ophthalmic pharmaceutical products — including anti-infective, anti-inflammatory, anti-allergic, glaucoma, and dry eye formulations — alongside cosmeceutical products (skin whitening, sunscreen, hair care) and ocular health food supplements. Its core manufacturing platform employs Blow-Fill-Seal (BFS) technology, introduced as the first such plant in Egypt in 2005, which forms, fills, and seals each ophthalmic bottle in a fully automated sterile process without human intervention. Orchidia holds WHO GMP, cGMP, ISO 9001, ISO 13485, ISO 14001, ISO 45001, and EU MDR certifications, and is ranked #1 in total sales value in the Egyptian ophthalmic market among 56 operating competitors.

The company operates a dual go-to-market model: a direct field sales force targeting hospitals, clinics, and pharmacies in Egypt, combined with a network of local distribution partners and agents across 40+ export markets in the Middle East, Africa, GCC, Russia, and CIS, with stated plans to enter the EU. Beyond product sales, Orchidia invests in physician engagement through Continuing Medical Education (CME) programs, including a WetLab training initiative launched in 2016 that has trained more than 500 junior ophthalmologists. Ownership is family-controlled by the Abbas family (Dr. Ossama Abbas as Chairman, Dr. Karim Ossama as CEO, Radwa Ossama as VP Technical Affairs), with institutional backing from SPE Capital (lead investor in 2026 consortium round alongside EBRD, Proparco, and BIO) marking the firm's second partnership with the family following a 2013-2017 investment. Revenue is not publicly disclosed, and the company operates as a private for-profit entity with 251-500 employees.

Name

Orchidia Pharmaceutical

Legal name

Orchidia Pharmaceutical Industries

Website

https://orchidiapharma.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

251–500 employees

Short description

Orchidia Pharmaceutical Industries is an Egyptian specialty pharmaceutical manufacturer founded in 1993, ranked #1 in Egypt's ophthalmic market, producing ophthalmic drugs, cosmeceuticals, and food supplements using Blow-Fill-Seal sterile manufacturing for distribution across 40+ countries.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Ophthalmic Goods Manufacturing (339115), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE)

Keywords

• Ophthalmic medications
• Pharmaceutical manufacturing
• Cosmeceutical products
• Ocular health supplements
• Sterile eye drops

Headquarters

HQ city

Cairo

HQ country

Egypt

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products Manufacturing and Sales: Orchidia manufactures and sells ophthalmic pharmaceutical products, cosmeceutical products, and food supplements. Revenue is generated through direct sales to healthcare providers and distribution partners across 40+ countries.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Orchidia Pharmaceutical Industries is an Egyptian pharmaceutical manufacturer that produces ophthalmic drugs (eye drops, suspensions, gels, and ointments for anti-infective, anti-inflammatory, anti-allergic, glaucoma, dry eye, and post-surgical care), cosmeceutical products (sunscreens, whitening serums, hair care), and food supplements for ocular health. Manufacturing is performed at the company's Al-Obour City facility using Blow-Fill-Seal (BFS) sterile technology — the first such plant in Egypt — with products exported to 40+ countries through direct sales and local distribution partners.

Product overview

Orchidia Pharmaceutical Industries is an Egyptian pharmaceutical company offering a diversified portfolio of specialized healthcare products across three main categories: Ophthalmic Products (eye drops, suspensions, gels, and ointments for anti-infective, anti-inflammatory, anti-allergic, glaucoma, and dry eye treatments), Cosmeceutical Products (skin whitening, moisturizing, sunscreen, and hair care), and Food Supplements (ocular health nutritional supplements). The company operates as a fully integrated pharmaceutical manufacturer, ranking #1 in Egypt's ophthalmic market with exports to over 40 countries. Key ophthalmic brands include Nevxal (NSAID for post-cataract surgery), Polyfresh (dry eye treatment with sodium hyaluronate), BRIMILLERGY (redness relief), and Twinzol (glaucoma combination therapy). Cosmeceutical offerings include Bio-Solari sunscreen line and Clarimond whitening serum. Food supplements include Ocuguard and Ocuguard LX for ocular health support.

Differentiator

Problem solved

Functional benefit

Products and services

• Nevxal Forte Nepafenac 3 mg/ml ophthalmic suspension for reducing the risk of macular edema associated with cataract surgery in diabetic patients. Targeted at ophthalmologists and hospital surgical departments.
• NEVXAL 0.1% Suspension Nepafenac 1 mg/ml ophthalmic suspension for prevention and treatment of pain and inflammation following cataract surgery, and reducing macular edema risk in diabetic patients. Targeted at ophthalmologists and surgical centers.
• Orchatears Plus Polyvidone (K25) 50 mg/ml ophthalmic solution for symptomatic treatment of dry eye syndrome. Targeted at ophthalmologists and patients with chronic dry eye.
• Natamycin 5% Sterile Ophthalmic Suspension Natamycin 5% sterile ophthalmic suspension for treatment of fungal blepharitis, conjunctivitis, and keratitis including Fusarium solani keratitis. Targeted at ophthalmologists managing fungal eye infections.
• Fortymox Plus Moxifloxacin 5 mg/ml + Dexamethasone 1 mg/ml ophthalmic solution for treatment of eye infections and prevention of post-surgical bacterial infections. Targeted at ophthalmologists.
• Duoeffectum Ofloxacin 3 mg/ml + Dexamethasone 1 mg/ml sterile ophthalmic suspension for eye and ear use, treating infections and inflammation associated with ocular surgery. Targeted at ophthalmologists and ENT specialists.
• CORNETEARS Vitamin A palmitate 1000 I.U./g aqueous eye gel for promotion of epithelial regeneration in burns, chemical burns, corneal ulcers, and dry eye treatment. Targeted at ophthalmologists and patients with corneal surface damage.
• GATISTAR 0.5% Gatifloxacin 0.5% ophthalmic solution for treatment of bacterial conjunctivitis caused by susceptible strains. Targeted at ophthalmologists and primary care providers.
• ORCHADEXOLINE Chloramphenicol 5 mg + Dexamethasone sodium phosphate 1 mg + Tetrahydrozoline HCL 0.25 mg sterile ophthalmic solution for acute and chronic infectious inflammations of cornea and conjunctiva. Targeted at ophthalmologists.
• Ocubesiflox Besifloxacin 6 mg/ml (0.6%) ophthalmic suspension for treatment of bacterial conjunctivitis caused by susceptible organisms. Targeted at ophthalmologists.
• Loteranol Comp Suspension Loteprednol etabonate 5 mg/ml + Tobramycin 3 mg/ml ophthalmic suspension for inflammatory conditions responsive to steroids where bacterial infection is present. Targeted at ophthalmologists.
• Polyfresh Extra SDU Sodium hyaluronate 0.1% + Carboxymethyl cellulose 0.5% unit dose vials for treatment of dry eye symptoms including chronic dry eye and Sjogren's syndrome. Targeted at ophthalmologists and patients with chronic dry eye.
• POLYFRESH Sodium hyaluronate 2 mg/ml ophthalmic solution for symptomatic treatment of dry eye syndrome and ocular fatigue. Targeted at ophthalmologists and patients with dry eye.
• SOLOFRESH Sodium hyaluronate 2 mg/ml sterile ophthalmic solution for symptomatic treatment of dry eye syndrome. Targeted at ophthalmologists and patients with dry eye.
• BRIMILLERGY Brimonidine tartrate 0.25 mg/ml sterile ophthalmic solution; selective alpha-2 adrenergic agonist for relieving eye redness due to minor irritations, acts in 1 minute with up to 8 hours duration. Targeted at ophthalmologists and patients with eye redness/allergies.
• Lenzy Multi-Purpose Contact Lens Solution Sterile isotonic solution with Poloxamer 407, Polyquaternium-1, and Hyaluronate sodium for multi-purpose contact lens care including cleaning, disinfection, hydration, protein removal, rinsing, and storage of soft and silicone hydrogel lenses. Targeted at contact lens wearers via pharmacies and optical retail.
• Twinzol SDU Dorzolamide 20 mg/ml + Timolol 5 mg/ml unit dose ophthalmic solution for elevated intraocular pressure in open-angle glaucoma. Targeted at ophthalmologists managing glaucoma patients.
• Twinzol Dorzolamide hydrochloride 22.26 mg/ml + Timolol maleate 6.83 mg/ml ophthalmic solution for elevated intraocular pressure when beta-blocker monotherapy is insufficient. Targeted at ophthalmologists.
• Timogel Timolol maleate 1 mg/g ophthalmic gel for treatment of elevated intraocular pressure, open-angle glaucoma, and certain secondary glaucomas. Targeted at ophthalmologists.
• Alphanova Brimonidine tartrate 1.5 mg/ml (0.15%) sterile ophthalmic solution for lowering elevated intraocular pressure in chronic open-angle glaucoma or ocular hypertension. Targeted at ophthalmologists.
• Perfect Care Multi-purpose contact lens solution with Poloxamer 407 for protein removal, cleaning, rinsing, disinfection, and storage of all soft contact lenses. Targeted at contact lens wearers via pharmacies and optical retail.
• Bio-Solari Sunscreen Cream UV filter sunscreen cream with broad spectrum protection against photoaging and deep skin damage, serving as emollient and skin conditioner. Targeted at dermatology and retail cosmeceutical consumers.
• Bio-Solari Sunscreen Lotion Broad spectrum UV protection sunscreen lotion for skin protection against photoaging. Targeted at retail cosmeceutical consumers.
• Bio-Solari Sunscreen Emulsion Lightweight sunscreen emulsion for broad spectrum UV protection. Targeted at retail cosmeceutical consumers.
• Clarimond Whitening Night Serum Night whitening serum for skin brightening, improving skin condition, moisturizing, antioxidant protection, and anti-inflammatory properties. Targeted at retail cosmeceutical consumers.
• Integrado Anti-Hair Loss Cream Hair conditioner and anti-hair loss cream with emollient and antioxidant properties for hair and scalp care. Targeted at retail cosmeceutical consumers.
• Ocuguard LX Soft gelatin capsules containing Ginkgo Biloba extract, Vitamin C, Nicotinamide, Vitamin B12, Beta-carotene, Vitamin E, Selenium, and Zinc for ocular health. Targeted at ophthalmologists, pharmacies, and nutraceutical consumers.
• Ocuguard Nutritional supplement for ocular health containing Ginkgo Biloba, vitamins, and minerals for diabetic retinopathy support, cognitive support, and neuroprotection. Targeted at ophthalmologists, pharmacies, and nutraceutical consumers.

Quantifiable outcome

• 500+ junior ophthalmologists trained since 2016 through WetLab program
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered minor.

• Ain Shams University - Faculty of MedicineminorStrategic or Co-development PartnerOrchidia collaborates with Faculty of Medicine at Ain Shams University for clinical trials and research collaborations.
• Mansoura University - Faculty of MedicineminorStrategic or Co-development PartnerOrchidia collaborates with Faculty of Medicine at Mansoura University for clinical trials and research collaborations.
• GRC (Genuine Research Center)minorStrategic or Co-development PartnerOrchidia collaborates with international research centers like GRC for carrying out clinical trials to fulfill research aims.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Bausch + Lomb (Bausch Health): Major global ophthalmic pharmaceutical and vision care company. Competes with Orchidia in ophthalmic drops, dry eye treatments, and contact lens care solutions, and serves as a benchmark multinational in the categories where Orchidia exports.
• Allergan (AbbVie): Global ophthalmic pharmaceutical major with leading brands in dry eye, glaucoma, and anti-infectives. Direct therapeutic category competitor to Orchidia in anti-infective, anti-inflammatory, and glaucoma treatments.
• Alcon: Global leader in ophthalmic pharmaceuticals, surgical devices, and vision care. Competes with Orchidia in ophthalmic pharmaceuticals globally and is the dominant multinational benchmark in the therapeutic categories Orchidia serves.

Emerging players

• Sun Pharma: Indian specialty pharmaceutical company with a significant ophthalmic division (Sun Ophthalmics). Comparable as an emerging-market-headquartered specialty ophthalmic manufacturer expanding into regulated and EM markets.
• Ajanta Pharma: Indian specialty pharmaceutical company with a strong ophthalmic and dermatology portfolio, with significant presence in Africa and emerging markets. Comparable as a specialty pharma manufacturer targeting similar EM geographies to Orchidia.

Direct peers

• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers, producing a broad range of branded and generic drugs including ophthalmic products. Direct competitor in the Egyptian ophthalmic market among the 45-56 players Orchidia leads.
• EVA Pharma: Leading Egyptian pharmaceutical manufacturer with a broad product portfolio including ophthalmic and specialty products. Competes directly with Orchidia in the Egyptian and export pharmaceutical markets across MEA.
• Pharco Pharmaceuticals: One of the largest privately held pharmaceutical companies in the MEA region, producing generics and specialty pharmaceuticals. Overlaps with Orchidia in ophthalmic and broader pharmaceutical manufacturing in Egypt and export markets.
• Amriya Pharmaceutical Industries: Egyptian pharmaceutical manufacturer producing a wide range of sterile and non-sterile dosage forms including ophthalmic preparations. Direct peer in Egypt's ophthalmic manufacturing segment.

Others

• EGA (Egyptian Generic Active Pharmaceutical Ingredients manufacturers): Egyptian and regional API/finished-dose manufacturers supplying and competing in the MEA pharmaceutical value chain. Adjacent ecosystem participants and indirect competitors relevant to understanding Orchidia's supply and competitive landscape.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@orchidiapharmaofficial?si=sfnWR7JfXqwIYdOM
• Facebookfacebook.com/orchidiapharmaceutical
• Instagraminstagram.com/orchidiapharma?igsh=NnR4b2t6MGM0b2J1
• Xx.com/OrchidiaP

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orchidia Pharmaceutical